U.S. Moves to Reclassify FDA-Approved, State-Licensed Marijuana; Cannabis Stocks Rally
Shares of several publicly traded cannabis companies climbed after the U.S. Department of Justice announced it was rescheduling FDA-approved and state-licensed marijuana from Schedule I to Schedule III and opening an expedited hearing on broader rescheduling. Executives hailed potential benefits for clinical research, tax treatment under Section 28…